Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA ...

MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...

Swiss generic and biosimilar medicines major Sandoz today announced that the European Commission (EC) has granted marketing ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...

The study comprised 161 patients split between three arms: EYP-1901 2mg (low dose; n=53); EYP-1901 3mg (high dose, n=54); and the standard of care, which was aflibercept 2mg every eight weeks (n=54).

In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...

Dr Garg highlights new data showing that high-dose aflibercept could effectively extend treatment intervals, reducing the burden on patients, particularly working-age adults with busy schedules. Of ...

Eylea (aflibercept) is a brand-name eye injection that’s prescribed for certain eye conditions including macular degeneration. The cost of the drug with and without insurance can depend on ...

Further information Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294).